Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BELLUS Health Inc | BLU | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
14.74 | 14.74 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 14.39 - 14.76 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 14.74 | USD |
BELLUS Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 1.87B | - | - | - | -10,193.34 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BELLUS Health News
Date | Time | Source | News Article |
---|---|---|---|
1/30/2024 | 09:56 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
8/14/2023 | 16:01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
7/10/2023 | 07:00 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section.. |
6/28/2023 | 16:21 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
6/28/2023 | 13:42 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
6/28/2023 | 10:05 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
6/28/2023 | 09:59 | PR Newswire (Canada) | Annonce boursière - Réservée aux médias et aux investisseurs.. |
6/28/2023 | 09:57 | PR Newswire (Canada) | Stock-exchange announcement - For media and investors only -.. |
6/16/2023 | 12:50 | Business Wire | BELLUS Health Inc. Announces Voting Results from Special.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLU Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 14.63 | 14.76 | 14.39 | 14.66 | 3,399,421 | 0.11 | 0.75% |
3 Years | 3.49 | 14.76 | 2.60 | 9.88 | 1,776,913 | 11.25 | 322.35% |
5 Years | 7.12 | 14.76 | 2.01 | 7.61 | 1,518,923 | 7.62 | 107.02% |
BELLUS Health Description
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions. |